Reach the next decision sooner
A first-in-human dose and escalation set from translational modeling, a Phase 2 dose chosen from exposure, a pediatric plan written while Phase 2 runs.
We identify where a model could save your program time and money: replace a study, resize a trial, support the dose or bring a decision forward. Then we build the models and deliver the evidence, documented to submission standard, at a fixed price and on a guaranteed date.
Example scan, fictional compound
Most programs buy modeling one study at a time. We start from the whole program and find where a model could replace, resize or speed up a study.
Every scan runs on a system we built in-house. It reads your program's own data alongside the scientific literature, the agencies' guidances and years of public regulatory decisions, approvals and rejections alike. Each opportunity is weighed against what reviewers have actually accepted and questioned, not only against what a method can do.
Every opportunity we find falls under one of them. Most programs have several, at every stage.
A first-in-human dose and escalation set from translational modeling, a Phase 2 dose chosen from exposure, a pediatric plan written while Phase 2 runs.
Concentration-QTc in place of a thorough QT study, PBPK in place of some DDI studies, virtual bioequivalence to size a BE trial and, in specific cases, support a waiver, sparse sampling in place of rich.
Exposure-response for efficacy and safety, trial simulation to test the design before you pay for it, covariate effects turned into dose adjustments.
Model-based meta-analysis against standard of care and competitors, the effect needed to differentiate, and an independent read on the data before licensing or investment.
FDA's 2024 oncology dosage guidance moves development away from taking the maximum tolerated dose into the registration trial by default. Sponsors are expected to compare dosages, with population PK, exposure-response and model-informed approaches among the tools to select them. It is a clear case of what a model-based strategy changes in a program: the dosages carried forward, the design of the dose-comparison trial, and the strength of the dosage justification presented to FDA.
Models support the randomized comparison of dosages that FDA recommends; they do not replace it. Source: FDA guidance for industry, Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases, August 2024.
You can start at any step. Most clients start with the Program Scan, steps 1 and 2, because it shows where the time and money are.
We read your development plan and data through our evidence system and list the points where modeling could change time, cost, risk or the chance of success.
For the opportunities worth taking, we define the question of interest and context of use, draft the ICH M15 assessment, sequence the work against the clinical plan and set out the regulatory interactions.
PopPK, exposure-response, PBPK, C-QTc, mechanistic models and trial simulation. The analysis plan is approved before modeling starts; every run is logged, re-executed and quality-controlled.
We write the modeling sections of briefing documents, place the reports in the eCTD, prepare you for FDA and EMA meetings, help you prepare requests to the FDA MIDD Paired Meeting Program and for scientific advice, and join the meeting where useful.
What a scan typically finds, from candidate selection to life cycle management. Pick a stage.
Agentic workflows built for pharmacometrics, running on our own servers, take over the time-consuming steps that can be automated: first drafts of datasets to the pharmacometrician's specification, data checks, run management, diagnostic plots, tables and figures. Every modeling choice, interpretation and recommendation is made by a senior pharmacometrician. Every dataset is checked against source, and every reported result is re-run from versioned code and verified before release. That is how we hold the dates and the prices. Where agents help, and where they do not →
At most, from a clean dataset to the report
Every package documented to the ICH M15 framework
Below a comparable CRO scope, on average
We guarantee the date and the documentation standard, never regulatory acceptance. Methods and verification →
A one-minute narrated film. Drug development has never offered more modeling options, or been harder to navigate. pmxstudio.ai finds where a model could save a program time and money: its proprietary system scans the program against the literature, agency guidance and years of approvals and rejections to find every real chance to accelerate, reduce or improve; it chooses the strategy, with an ICH M15 assessment for each opportunity worth taking; implements the models at a fixed price, in up to four weeks from a clean dataset, with every result verified; and prepares the filing and the agency meeting. Senior-led, fast, and priced to compete. It ends with an invitation to discuss your program.
Senior pharmacometricians and quantitative clinical pharmacologists from big pharma and leading CROs lead every program. The expert who scopes your program leads it; clinical, biostatistics and regulatory specialists join when the question needs them.
Exposure-response for efficacy and safety, and a dose-justification memo for Project Optimus.
Population PK from SAD/MAD data and the dose rationale for the end-of-Phase-1 meeting.
Pre-specified concentration-QTc analysis of pooled Phase 1 data, including the CSR section.
Pre-specified selection protocol and acceptance criteria, with failures reported next to successes. See the benchmark.
A 15-minute call with the pharmacometrician who would lead the work, about where your program is and the next decision. A fixed proposal follows within 48 hours.